1,179 results match your criteria Hurthle Cell Carcinoma


Hürthle-cell neoplasms of the thyroid: An algorithmic approach to pathologic diagnosis in light of molecular advances.

Semin Diagn Pathol 2020 May 4. Epub 2020 May 4.

Hospital of the University of Pennsylvania, Department of Pathology, Philadelphia, (PA), United States. Electronic address:

Our understanding of neoplasia is evolving at a rapid pace in these exciting times, where recent molecular pathology advances are reinforcing and fine tuning morphological divisions and classification. Thyroid gland neoplasia in general, and Hürthle-cell neoplasms in particular, are no exception in the current era of histopathology-molecular biology paradigm. In this review paper, we discuss the rationale that led pathologists in the past to separate Hürthle-cell neoplasms into its own dedicated diagnostic category, and provide an algorithmic approach to the differential diagnosis of oncocytic lesions of the thyroid. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1053/j.semdp.2020.03.004DOI Listing

Histologic Features of BRAF V600E-Mutant Anaplastic Thyroid Carcinoma.

Histopathology 2020 May 19. Epub 2020 May 19.

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, United States.

Background: Treatment with a BRAF inhibitor, alone or in combination with a MEK inhibitor, may be considered for BRAF-mutant ATC. The purpose of this study was to characterize the histology of BRAF V600E-mutant ATC.

Methods: We identified 28 ATC that were consecutively resected between 2003-2019. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.14144DOI Listing

Clinical characteristics and prognostic factors of Hurthle cell carcinoma: a population based study.

BMC Cancer 2020 May 12;20(1):407. Epub 2020 May 12.

Department of International Medical Services, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Beijing, China.

Background: Thyroid Hurthle cell carcinoma (HCC) is a rare disease with high risk of invasion and metastasis and poor prognosis. The clinical characteristics, prognosis and treatment of HCC are still controversial, and clinical data are still limited to some case reports. Therefore, understanding the characteristics and survival factors of HCC is clinically necessary. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-020-06915-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7216584PMC

Thyroid cancer associated with Hashimoto thyroiditis: similarities and differences in an endemic area.

J Egypt Natl Canc Inst 2020 Jan 17;32(1). Epub 2020 Jan 17.

Surgical oncology unit, Mansoura University Oncology center, Mansoura, Egypt.

Background: Hashimoto thyroiditis (HT) is an autoimmune lymphocytic thyroiditis and is the most common form of thyroid inflammatory diseases. The association of HT with papillary thyroid carcinoma (PTC) has been described. PTC is the most common form of malignancy associated with HT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s43046-020-0017-9DOI Listing
January 2020

Signification of forkhead box A1 (FOXA1) expression in thyroid cancers.

J Egypt Natl Canc Inst 2019 Dec 30;31(1):11. Epub 2019 Dec 30.

Research Unit UR14ES17, Medicine Faculty, University of Sousse, Sousse, Tunisia.

Background: Forkhead box A1 (FOXA1) plays an important role in several tumors. This study investigated the potential role of FOXA1 expression in thyroid tumors. We conducted a retrospective study of 110 thyroid lesions and tumors diagnosed during 1995-2018. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s43046-019-0011-2DOI Listing
December 2019

Hurthle Cell Adenoma with Micro-Papillary Carcinoma and Parathyroid Adenoma in a Transplant Recipient with Graft Failure: A Case Report.

Gulf J Oncolog 2020 Jan;1(32):66-70

Kuwait Cancer Control Center, Kuwait.

Chronic immunosuppression is known to cause an increased risk of cancers in organ transplant recipients leading to the rise in morbidity and mortality among these patients. Recent studies have observed that thyroid lesions are more frequently encountered in kidney transplant recipients. A 45-year-old woman with history of chronic hypertension, kidney transplant and graft failure, was admitted for assessment for a second renal transplant and detected to have a thyroid nodule by ultrasound (US). Read More

View Article

Download full-text PDF

Source
January 2020

GABPA-dependent down-regulation of DICER1 in follicular thyroid tumours.

Endocr Relat Cancer 2020 Mar 1. Epub 2020 Mar 1.

C Juhlin, Karolinska University Hospital, Karolinska Institutet Department of Oncology Pathology, Stockholm, Sweden.

Mutations in the miRNA enzyme gene DICER1 have been reported in several endocrine malignancies and is associated to the rare tumour-predisposing DICER1 syndrome. DICER1 mutations have been reported in subsets of follicular thyroid carcinoma (FTC), but the role of DICER1 in follicular thyroid tumorigenesis has not been extensively studied. In this study, we investigate the role of DICER1 in 168 follicular thyroid tumours and in an FTC cell line. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1530/ERC-19-0446DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7159166PMC

[Thyroid follicular cell tumors: cytohistological comparisons in the context of the new international classification].

Arkh Patol 2020 ;82(1):15-22

National Medical Research Center of Endocrinology, Ministry of Health of Russia, Moscow, Russia.

Objective: To carry out a correlation retrospective analysis of the histological and cytological findings of follicular cell neoplasms over a two-year period after the publication of the new WHO classification of thyroid tumors (2017), which identifies a category of follicular tumors of uncertain malignant potential (T-UMP).

Material And Methods: The investigators of the Clinic, National Medical Research Center for Endocrinology, Ministry of Health of Russia, made a cytohistological comparison of morphological findings, by using the material of surgically removed follicular cell neoplasms.

Results: The investigation showed the lack of unreasonably common usage of the histological classification category of T-UMP (3. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.17116/patol20208201115DOI Listing
February 2020

Metastatic Anaplastic Thyroid Carcinoma in Complete Remission: Morphological, Molecular, and Clinical Work-Up of a Rare Case.

Endocr Pathol 2020 Mar;31(1):77-83

Department of Oncology-Pathology, Karolinska Institutet, BioClinicum J6:20, SE-171 76, Stockholm, Sweden.

Anaplastic thyroid carcinoma (ATC) exhibits an exceedingly poor prognosis, and the current treatment options are, for most cases, palliative by nature. Few reports of long-time survivors exist, although in these patients, tumors often were limited to the thyroid and/or regional lymph nodes. We describe a 64-year-old male who developed a rapidly growing mass in the left thyroid lobe. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12022-020-09606-5DOI Listing

METASTATIC HÜRTHLE CELL CARCINOMA PRESENTING WITH LOW FREE THYROXINE, SEVERE HYPERCALCEMIA AND SPURIOUS GROWTH HORMONE PRODUCTION.

AACE Clin Case Rep 2019 May-Jun;5(3):e204-e209. Epub 2019 Apr 25.

Objective: Hürthle cell tumors constitute about 5% of thyroid neoplasms. They have malignant potential, behaving very aggressively compared to other differentiated thyroid cancers. The objective of this case report is to describe a case of a Hürthle cell carcinoma with a single large metastasis in the liver presenting almost 17 years after hemithyroidectomy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4158/ACCR-2018-0440DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6876938PMC

International Multi-institutional Experience with the Transoral Endoscopic Thyroidectomy Vestibular Approach.

J Laparoendosc Adv Surg Tech A 2020 Mar 17;30(3):278-283. Epub 2020 Jan 17.

Division of Metabolic, Endocrine and Minimally Invasive Surgery, Department of Surgery, Mount Sinai Hospital, Icahn School of Medicine at Mount Sinai, New York, New York.

Surgical approaches to thyroidectomies have undergone a rapid evolution over the past three decades. Transoral endoscopic thyroidectomy vestibular approach (TOETVA) is currently the latest remote access procedure for the treatment of benign and malignant thyroid disease. The purpose of this article is to present the results of TOETVA from five different international institutions. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/lap.2019.0645DOI Listing

Hürthle Cell Thyroid Adenoma Showing Avid Uptake on 18F-PSMA-1007 PET/CT.

Clin Nucl Med 2020 Mar;45(3):223-224

From the Department of PET/CT, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, Zhejiang, China.

We report the case of a 74-year-old man with suspected recurrent prostate carcinoma who underwent F-PSMA-1007 PET/CT for restaging the disease. PET/CT imaging presented an incidentaloma with intense F-PSMA-1007 uptake in the right thyroid lobe. Biopsy and genomic sequencing test confirmed the diagnosis of Hürthle cell thyroid adenoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/RLU.0000000000002873DOI Listing

A 15 year institutional experience of well-differentiated follicular cell-derived thyroid carcinomas; impact of the new 2017 TNM and WHO Classifications of Tumors of Endocrine Organs on the epidemiological trends and pathological characteristics.

Endocrine 2020 Mar 14;67(3):630-642. Epub 2019 Dec 14.

Department of Histology, George Emil Palade University of Medicine, Pharmacy, Sciences, and Technology of Targu-Mureş, 38 Gh. Marinescu Street, 540139, Targu-Mureş, Romania.

Purpose: Our study aimed to describe the evolution of the rate of pathological subtypes of well-differentiated follicular-cell derived thyroid carcinomas (DTCs) in the Department of Pathology, Emergency County Hospital Targu-Mures, Romania over a 15 year period and to assess the impact the new 2017 WHO and TNM classifications of thyroid tumors had on our cases.

Methods: The pathological data were retrieved from the original pathological reports. After applying the exclusion criteria the remaining cases were reviewed on a double-headed microscope and reclassified according to the 2017 WHO and TNM staging system. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-019-02158-7DOI Listing

Comprehensive DNA Methylation Profiling Identifies Novel Diagnostic Biomarkers for Thyroid Cancer.

Thyroid 2020 Feb 9;30(2):192-203. Epub 2020 Jan 9.

Genome Editing Research Center; Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea.

There are no reliable biomarkers to accurately differentiate indolent thyroid tumors from more aggressive thyroid cancers. This study aimed to develop new DNA methylation markers for diagnosis and recurrence risk stratification of papillary thyroid carcinoma (PTC). Thyroid tumor-specific DNA methylation profiling was investigated in 34 fresh frozen tissues, which included nontumor ( = 7), noninvasive follicular thyroid neoplasms with papillary-like nuclear features (NIFTP,  = 6) and PTC ( = 21), using the Illumina HumanMethylation EPIC array. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2019.0011DOI Listing
February 2020
5 Reads
4.493 Impact Factor

Combined use of galectin-3 and thyroid peroxidase improves the differential diagnosis of thyroid tumors.

Neoplasma 2020 Jan 18;67(1):164-170. Epub 2019 Nov 18.

Department of Otorhinolaryngology and Head and Neck Surgery, University Hospital Motol, First Faculty of Medicine, Charles University, Prague, Czech Republic.

The differential diagnosis of well-differentiated tumors of follicular cell origin remains the most problematic task in thyroid pathology. Specific morphologic criteria (capsular and/or vascular invasion, nuclear characteristics) are crucial in the diagnosis of these neoplasms. However, the assessment of malignant features is inconclusive in some cases. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4149/neo_2019_190128N86DOI Listing
January 2020

Concurrence of Papillary Thyroid Carcinoma and Hürthle Cell Carcinoma in an Iranian Woman with Hashimoto's Thyroiditis.

Iran J Pathol 2019 22;14(4):342-346. Epub 2019 Sep 22.

General Physician, 553 Army Hospital, Qazvin, Iran.

The most usual form of the endocrine carcinoma is thyroid cancer (TC). In addition to papillary thyroid carcinoma (PTC), recent studies revealed incidence of RET/PTC rearrangement in other tumors, like Hürthle cell carcinoma (HCC) and even in non-carcinomatous disorders like Hashimoto's thyroiditis. Here, we present a case with concurrence of papillary thyroid carcinoma and Hürthle cell carcinoma. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.30699/ijp.2019.99544.1986DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6824768PMC
September 2019

Analysis of Malignant Thyroid Neoplasms with a Striking Rise of Papillary Microcarcinoma in an Endemic Goiter Region.

Indian J Otolaryngol Head Neck Surg 2019 Oct 20;71(Suppl 1):121-130. Epub 2017 Jul 20.

2Department of Surgery, Sree Uthradom Thirunal Academy of Medical Sciences, Thiruvananthapuram, Kerala India.

According to National Cancer Registry Program, Thiruvananthapuram district of Kerala, has the highest relative frequency of thyroid carcinomas; nevertheless, limited data exist regarding its socio-demographic and clinico-pathological characteristics. The aims of the study were to assess the: (1) demographic characteristics, (2) histopathological features and the relative frequency of various thyroid carcinoma cases and papillary thyroid carcinoma (PTC) subtypes, (3) rising trend of papillary microcarcinomas, and (4) associated lesions. A retrospective study wherein 170 cases of thyroid malignancies reported in our single institution over a period of 8 years period was reviewed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12070-017-1156-8DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6848467PMC
October 2019

The role of molecular testing in the diagnosis of medullary thyroid cancer: A case report of oncocytic medullary thyroid carcinoma and review of the literature.

Am J Otolaryngol 2020 Jan - Feb;41(1):102312. Epub 2019 Nov 11.

Thyroid, Head, and Neck Cancer (THANC) Foundation, 10 Union Square East, Suite 5B, New York, NY 10003, USA; Department of Otolaryngology-Head and Neck Surgery, Icahn School of Medicine at Mount Sinai, 10 Union Square East, Suite 5B, New York, NY 10003, USA.

Background: Medullary thyroid carcinoma (MTC) is a somewhat rare, particularly aggressive form of thyroid cancer. The authors present what we believe to be the first case of MTC diagnosed solely on the basis of molecular testing, as well as a review of the literature concerning this topic and oncocytic variants of MTC.

Case Description: A 30-year-old female patient with a 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.amjoto.2019.102312DOI Listing

Combined quantitation of HMGA2 mRNA, microRNAs, and mitochondrial-DNA content enables the identification and typing of thyroid tumors in fine-needle aspiration smears.

BMC Cancer 2019 Oct 28;19(1):1010. Epub 2019 Oct 28.

Institute of Molecular and Cellular Biology, Novosibirsk, 630090, Russia.

Background: Analysis of molecular markers in addition to cytological analysis of fine-needle aspiration (FNA) samples is a promising way to improve the preoperative diagnosis of thyroid nodules. Nonetheless, in clinical practice, applications of existing diagnostic solutions based on the detection of somatic mutations or analysis of gene expression are limited by their high cost and difficulties with clinical interpretation. The aim of our work was to develop an algorithm for the differential diagnosis of thyroid nodules on the basis of a small set of molecular markers analyzed by real-time PCR. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1186/s12885-019-6154-7DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6819494PMC
October 2019
1 Read

Evaluation of thyroid nodules classified as Bethesda category III on cytology and their malignancy rate: An institutional experience.

Cytojournal 2019 16;16:18. Epub 2019 Sep 16.

Address: Department of Pathology, Salmaniya Medical Complex, Manama, Bahrain.

Background: Thyroid gland nodules are common and fine-needle aspiration (FNA) is the gold standard for screening those nodules. The Bethesda system for reporting thyroid cytolopathology standardized reporting thyroid nodules aspirations, but atypia of undetermined significance or follicular lesion of undetermined significance (Bethesda category III) was the most controversial category. The aim of our study is to review our institutional experience and analyze the clinical implications of making a diagnosis of AUS/FLUS (Bethesda category III). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4103/cytojournal.cytojournal_4_19DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764167PMC
September 2019
1 Read

Oncocytic Variant of Medullary Thyroid Carcinoma - A Case Report.

Iran J Pathol 2019 27;14(1):83-87. Epub 2018 Dec 27.

MBBS, MD Pathology, DNB Pathology, Associate Professor, Department of Pathology, Kasturba Medical College, Manipal University, Manipal, Karnataka, India.

Medullary thyroid carcinoma (MTC) is a rare tumor arising from parafollicular C-cells. The oncocytic variant of MTC is an extremely rare diagnosis, with less than 20 cases reported. Here we present the case of a 36-year-old male patient with complaints of neck swelling and dysphagia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.30699/IJP.14.1.83DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708566PMC
December 2018
2 Reads

Effect of adjuvant radioactive iodine therapy on survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma).

PeerJ 2019 27;7:e7458. Epub 2019 Aug 27.

Department of Head, Neck & Thyroid Surgery, Zhejiang Provincial People's Hospital, People's Hospital of Hangzhou Medical College, Hangzhou, Zhejiang, P.R.China.

Purpose: Radioactive iodine (RAI) is widely used for adjuvant therapy after thyroidectomy, while its value for thyroid cancer has been controversial recently. The primary objectives of this study were to clarify the influence of Radioactive iodine (RAI) on the survival in rare oxyphilic subtype of thyroid cancer (Hürthle cell carcinoma, HCC).

Methods: Patients diagnosed with oxyphilic thyroid carcinoma from 2004 to 2015 were extracted from the Surveillance, Epidemiology, and End Results Program database. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.7717/peerj.7458DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6716497PMC
August 2019
2 Reads

EVOLUTION OF TARGETED THERAPIES FOR THYROID CARCINOMA.

Authors:
Steven I Sherman

Trans Am Clin Climatol Assoc 2019 ;130:255-265

HOUSTON, TEXAS.

Although treatment options for patients with advanced and metastatic thyroid carcinoma were historically limited, developments in the past 15 years in understanding the pathogenesis of these malignancies have permitted identification of novel targeted therapies to improve outcomes. Five individual drugs and one combination therapy have achieved regulatory approval since 2011, all showing improvements in progression-free survival or high response rates. More selective targeting of mutated oncogenic kinases is leading to increasing efficacy with fewer toxicities, at least in early human trials. Read More

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6736004PMC
February 2020

Salivary duct carcinoma: A case report of oncocytic variant with possible treatment implications and review of literature.

Pathol Res Pract 2019 Oct 24;215(10):152549. Epub 2019 Aug 24.

Department of Pathology, University of Tennessee Health Sciences Center (UTHSC), Memphis; Department of Pathology, Methodist University Hospital (MUH), Memphis. Electronic address:

Salivary duct carcinoma (SDC) is an aggressive malignancy, resembling high-grade ductal carcinoma of the breast. Histologically, it shows cords and nests with cribriforming, marked nuclear atypia, comedonecrosis, perineural, and lymphovascular invasion. We report a rare case of SDC in a 61-year-old woman presenting with facial asymmetry, dysphagia, and cervical lymphadenopathy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.prp.2019.152549DOI Listing
October 2019
3 Reads

Clinicopathological features of melanotic and non-melanotic oncocytic lesions of the nasopharynx.

Pathology 2019 Oct 21;51(6):600-604. Epub 2019 Aug 21.

Department of Anatomical and Cellular Pathology, Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong.

Oncocytic metaplastic lesions of the nasopharynx are rare benign entities which are divided into melanotic and non-melanotic forms. Less than 40 non-melanotic and 30 melanotic cases have been reported in the literature. We present the largest known case series to date of melanotic oncocytic metaplasia and more than 20 cases of non-melanotic oncocytic metaplasia. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.pathol.2019.04.009DOI Listing
October 2019
3 Reads

Targeted Treatment Options of Recurrent Radioactive Iodine Refractory Hürthle Cell Cancer.

Cancers (Basel) 2019 Aug 15;11(8). Epub 2019 Aug 15.

Department of Pathology, Leiden University Medical Center, 2333 ZA Leiden, The Netherlands.

: To evaluate the efficacy and treatment rationale of Hürthle cell carcinoma (HCC) following a patient with progressive and metastatic HCC. HCC was recently shown to harbor a distinct genetic make-up and the mitogen-activated protein kinase (MAPK) and phosphatidylinositol 3-kiase (PI3K)/AKT signaling pathways are potential targets for anti-cancer agents in the management of recurrent HCC. The presence or absence of gene variants can give a rationale for targeted therapies that could be made available in the context of drug repurposing trials. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3390/cancers11081185DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6721552PMC
August 2019
2 Reads

Keap1/Nrf2 Signaling: A New Player in Thyroid Pathophysiology and Thyroid Cancer.

Front Endocrinol (Lausanne) 2019 2;10:510. Epub 2019 Aug 2.

Service of Endocrinology, Diabetology and Metabolism, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.

The Keap1/Nrf2 pathway is a key mediator of general redox and tissue-specific homeostasis. It also exerts a dual role in cancer, by preventing cell transformation of normal cells but promoting aggressiveness, and drug resistance of malignant ones. Although Nrf2 is well-studied in other tissues, its roles in the thyroid gland are only recently emerging. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3389/fendo.2019.00510DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6687762PMC
August 2019
4 Reads

Sporadic renal hybrid oncocytic/chromophobe tumor in a young man: A case report.

Medicine (Baltimore) 2019 Aug;98(33):e16641

Department of Urology, the First Affiliated Hospital of Anhui Medical University, Hefei, China.

Rationale: Hybrid oncocytic/chromophobe tumor (HOCT) is defined as tumor composed of renal oncocytoma (RO) and chromophobe renal cell carcinoma (CHRCC). Sporadic HOCT is extremely rare, the preoperative diagnosis is difficult, and no guidelines for clinical therapy. We report a case who is the youngest male patient of sporadic HOCT in the world, review the previously reported cases, and share the clinical features, diagnosis, treatment, and prognosis of HOCT. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/MD.0000000000016641DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6831243PMC
August 2019
2 Reads

Long-term outcome of rare oncocytic papillary (Hürthle cell) thyroid carcinoma following (adjuvant) initial radioiodine therapy.

Eur J Nucl Med Mol Imaging 2019 Nov 13;46(12):2526-2535. Epub 2019 Aug 13.

Department of Nuclear Medicine, University Hospital, LMU Munich, Marchioninistr. 15, 81377, Munich, Germany.

Purpose: Oncocytic (Hürthle cell) papillary thyroid carcinoma (OPTC) is a rare variant of the papillary thyroid carcinoma (PTC) which comprises approximately 1 to 11 % of PTC cases. Its clinical course and prognosis have not been comprehensively documented and the clinical outcome remains a controversial issue. Therefore, we investigated the long-term prognosis after thyroidectomy and (adjuvant) initial radioactive iodine therapy (RIT) of OPTC compared to PTC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00259-019-04456-8DOI Listing
November 2019
1 Read

Characterization of Activating Mutations of the Gene in Papillary Thyroid Carcinomas.

Thyroid 2019 09;29(9):1279-1285

Department of Pathology and Laboratory Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Genetic alterations activating the mitogen-activated protein kinase (MAPK) signaling pathway, most commonly and mutations, are common in papillary thyroid carcinoma (PTC). Somatic mutations of the gene, also known as mitogen-activated protein kinase kinase 1 (), coding for a signaling protein downstream of BRAF, have been found in several cancer types. The goal of this study was to investigate if functional mutations occur in thyroid cancer (TC). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1089/thy.2019.0065DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6913803PMC
September 2019
4 Reads

Prognostic Significance of Extent of Invasion in Poorly Differentiated Thyroid Carcinoma.

Thyroid 2019 09;29(9):1255-1261

Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts.

The 2017 World Health Organization (WHO) Classification of Tumors of Endocrine Organs defines poorly differentiated thyroid carcinoma (PDTC) as a tumor with conventional criteria of malignancy (capsular penetration or vascular invasion) with solid, insular, or trabecular growth, a lack of nuclear features of papillary thyroid carcinoma, and increased mitotic activity, tumor necrosis, or convoluted nuclei. The extent of invasion has been shown to be prognostic in follicular thyroid carcinoma and Hürthle cell carcinoma. Our aim was to evaluate how extent of invasion impacts clinical outcome for PDTC. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/thy.2019.0263
Publisher Site
http://dx.doi.org/10.1089/thy.2019.0263DOI Listing
September 2019
5 Reads
4.493 Impact Factor

Cytopathology approach to rare salivary gland lesions with oncocytic features.

Diagn Cytopathol 2019 Oct 8;47(10):1090-1099. Epub 2019 Aug 8.

The Leopold G. Koss Department of Cytopathology, Montefiore Medical Center/Albert Einstein College of Medicine, New York, New York.

Salivary glands located in the head and neck area are known to have different lesions with prominent oncocytic features. Fine needle aspiration is usually the initial approach in the management of these lesions, whether they represent neoplastic or non-neoplastic processes. Owing to the limited material present upon cytopathologic examination, knowledge of variants and subtypes of various oncocytic lesions that can occur in this area is of major importance to provide the most accurate interpretation to the patients and clinicians. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24297DOI Listing
October 2019
4 Reads

Embolization of iliac metastasis during lenvatinib treatment in patient with advanced Hürthle cell thyroid carcinoma.

Future Oncol 2019 Aug 6;15(24s):35-40. Epub 2019 Aug 6.

Department of Medical Sciences & Public Health, Postgraduate School of Endocrinology & Metabolic Diseases, University of Cagliari, Cagliari, Italy.

Lenvatinib is a tyrosine kinase inhibitor (TKI) with antiproliferative and antiangiogenic effects indicated for the treatment of progressive, locally advanced or metastatic progressive thyroid carcinoma, refractory to radioactive iodine therapy. Antiangiogenic therapies induce ischemic necrosis of tumor tissue, with increased risk of hemorrhagic complications. The management of hemorrhagic risk is based on precautionary measures and for any surgical procedure, it is advised to interrupt the treatment in order to avoid complications. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/fon-2019-0184DOI Listing
August 2019
3 Reads

Subcategorisation of AUS/FLUS thyroid lesions as per the 2017 Bethesda System for Reporting Thyroid Cytopathology: a retrospective study from a tertiary care centre analysing risk of malignancy (ROM) of the different subcategories.

J Clin Pathol 2019 Nov 2;72(11):771-777. Epub 2019 Aug 2.

Pathology, All India Institute of Medical Sciences, New Delhi, India.

Aims: The 2017 Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) recommends subclassification of atypia of undetermined significance (AUS)/follicular lesion of undetermined significance (FLUS) into six subcategories. The present study evaluates the risk of malignancy (ROM) and risk of neoplasm (RON) among these.

Methods: All thyroid aspirates reported as AUS/FLUS over a 4. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1136/jclinpath-2019-205985DOI Listing
November 2019
4 Reads

PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid.

Mod Pathol 2019 12 4;32(12):1734-1743. Epub 2019 Jul 4.

Department of Oncology, University of Turin, at Città della Salute Hospital, Torino, Italy.

The hyalinizing trabecular adenoma/tumor is a rare and poorly characterized follicular-derived thyroid neoplasm recently shown to harbor recurrent PAX8-GLIS1 or PAX8-GLIS3 gene fusions. Here we sought to define the repertoire of genetic alterations of hyalinizing trabecular tumors, and whether PAX8-GLIS3 fusions are pathognomonic for hyalinizing trabecular tumors. A discovery series of eight hyalinizing trabecular tumors was subjected to RNA-sequencing (n = 8), whole-exome sequencing (n = 3) or targeted massively parallel sequencing (n = 5). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0313-xDOI Listing
December 2019
9 Reads

Medullary carcinoma of thyroid mimicking Hurthle cell neoplasm on cytology: a diagnostic dilemma.

Diagn Cytopathol 2019 Sep 13;47(9):943-947. Epub 2019 Jun 13.

Department of Pathology and ENT, ESIC Medical College & Hospital, Faridabad, Haryana, India.

Medullary carcinoma of thyroid (MCT) is a neuroendocrine neoplasm derived from the parafollicular cells or C cells. It constitutes 5% of thyroid carcinomas. We present a case of 36-year-old female with a left lower lobe thyroid swelling since 8 to 9 years. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24220DOI Listing
September 2019
12 Reads

Phase 2 study of vascular endothelial growth factor trap for the treatment of metastatic thyroid cancer.

Cancer 2019 09 7;125(17):2984-2990. Epub 2019 Jun 7.

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.

Background: Several multitargeted tyrosine kinase inhibitors (TKIs) have demonstrated activity in patients with thyroid cancer that is refractory to radioactive iodine (RAI). The antitumor effect is attributed at least in part to the ability of these TKIs to inhibit angiogenesis in these vascular tumors. Vascular endothelial growth factor (VEGF) Trap (VT) is a recombinantly produced fusion protein consisting solely of human sequences for VEGF receptors 1 and 2 extracellular domains and human immunoglobulin 1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cncr.32046DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6773269PMC
September 2019
20 Reads

Apocrine epithelial-myoepithelial carcinoma of the parotid gland with concurrent oncocytic change: a novel variant.

Oral Surg Oral Med Oral Pathol Oral Radiol 2019 Nov 1;128(5):530-537. Epub 2019 Apr 1.

The State Key Laboratory Breeding Base of Basic Science of Stomatology & Key Laboratory of Oral Biomedicine Ministry of Education, School & Hospital of Stomatology, Wuhan University, Wuhan, China; Oral Histopathology Department, School and Hospital of Stomatology, Wuhan University, Wuhan, China. Electronic address:

Epithelial-myoepithelial carcinoma (EMCa) is a rare, low-grade, malignant salivary gland tumor. Here, we report an unusual case of an EMCa with extensive apocrine and oncocytic changes. The tumor occurred in the left parotid gland of a 68-year-old male. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.oooo.2019.03.015DOI Listing
November 2019

Thyroid nodules with Hürthle cells: the malignancy risk in relation to the FNA outcome category.

J Endocrinol Invest 2019 Nov 10;42(11):1319-1327. Epub 2019 May 10.

Department of Morphometry of Endocrine Glands, Chair of Endocrinology, Medical University of Lodz, Pomorska Str 251, 92-213, Lodz, Poland.

Purpose: The aim was to find whether the presence of Hürthle cells (HC) in a smear influences the categorization of FNA results or the risk of malignancy (RoM) of particular categories of cytological diagnosis.

Methods: 25,220 FNA performed in a single center in years 2005-2017 were analyzed. Almost all the examined patients were exposed to moderate iodine deficiency for most of their lives. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s40618-019-01055-0DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6790181PMC
November 2019
4 Reads

Diagnostic performance of thyroid ultrasound in Hürthle cell carcinomas.

Arch Endocrinol Metab 2019 May-Jun;63(3):300-305. Epub 2019 Apr 25.

Laboratório de Endocrinologia Celular e Molecular (LIM25), Hospital das Clínicas da Faculdade de Medicina, Universidade de São Paulo, São Paulo, SP, Brasil.

Objective: Hürthle cell carcinomas (HCCs) of the thyroid have been recently reclassified as a separate entity due to their distinct clinical and molecular profiles. Few studies have assessed the ability of preoperative characteristics in differentiating HCCs from Hürthle cell adenomas (HCAs) due to the low prevalence of both lesions. This study aimed to compare the preoperative features of HCCs and HCAs and evaluate the diagnostic performance of ultrasound in distinguishing between both. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20945/2359-3997000000131DOI Listing
September 2019
3 Reads

LATERAL NECK DISSECTION FOR AGGRESSIVE VARIANTS OF WELL-DIFFERENTIATED THYROID CANCER.

Endocr Pract 2019 Apr;25(4):328-334

Well-differentiated thyroid cancer (WDTC) is characterized by favorable disease course and excellent survival. However, some histologic subtypes, known as aggressive histologic variants (AHVs), present a more aggressive behavior than conventional WDTC. The aim of this study was to evaluate the pattern of nodal involvement and factors influencing prognosis in N1b patients with AHVs. Read More

View Article

Download full-text PDF

Source
http://journals.aace.com/doi/10.4158/EP-2018-0503
Publisher Site
http://dx.doi.org/10.4158/EP-2018-0503DOI Listing
April 2019
21 Reads

Early Calcium Supplementation After Total Thyroidectomy Can Prevent Symptomatic Hypocalcemia - Findings from a Retrospective Study.

Gulf J Oncolog 2019 Jan;1(29):60-65

Department of Surgical Oncology, Malabar Cancer Centre, Thalassery, Kannur, Kerala, India.

Introduction: Thyroidectomy for thyroid cancers and central neck dissection are considered as independent predictors of postoperative hypocalcemia. Post-surgical hypocalcemia is the most common and often the most difficult long-term consequence of thyroid surgeries. Management of hypocalcemia is done with calcium supplementation, but there is no consensus on the timing and the amount of calcium supplementation. Read More

View Article

Download full-text PDF

Source
January 2019
5 Reads

Is thyroid nodule volume predictive for malignancy?

Arch Endocrinol Metab 2019 Mar 21;63(4):337-344. Epub 2019 Mar 21.

Yildirim Beyazit University, School of Medicine, Department of Endocrinology and Metabolism, Ankara, Turkey.

Objective: We aimed to determine the roles of preoperative thyroid nodule diameter and volume in the prediction of malignancy.

Subjects And Methods: The medical records of patients who underwent thyroidectomy between January 2007 and December 2014 were reviewed. The nodule diameters were grouped as < 1 cm, 1-1. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.20945/2359-3997000000113DOI Listing
March 2019
3 Reads

The key radiologic and cytomorphologic features of oncocytic and oncocytoid lesions of the salivary gland.

Diagn Cytopathol 2019 Jun 26;47(6):617-636. Epub 2019 Mar 26.

Department of Pathology & Laboratory Medicine, Hospital of the University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania.

Oncocytic and oncocytoid lesions represent a distinct subset of salivary gland lesions. True oncocytic lesions of the salivary gland are entirely composed of oncocytes. These are characterized by the presence of abundant eosinophilic granules due to the presence of abundant cytoplasmic mitochondria. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/dc.24175DOI Listing
June 2019
2 Reads

An Insight into the Utility of Sub-Categorisation of Atypia of Undetermined Significance for Risk Stratification: A Retrospective Study on an Indian Cohort with Histopathological Correlation.

Acta Cytol 2019 19;63(3):182-188. Epub 2019 Mar 19.

Department of Pathology, Christian Medical College, Vellore, India.

Background: Atypia of undetermined significance or follicular lesion of undetermined significance (AUS/FLUS) criterion in thyroid fine-needle aspirates (FNAs) has been a heterogeneous entity with much inter-observer variation. Sub-categorisation of AUS/FLUS has been observed to play an effective role in risk stratification. We aimed to validate AUS/FLUS sub-categorisation in correlation with the spectrum of malignancy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1159/000496600DOI Listing
June 2019
8 Reads

Short Review: Genomic Alterations in Hürthle Cell Carcinoma.

Thyroid 2019 04;29(4):471-479

2 Department of Internal Medicine, Division of Endocrinology, Department of Biochemistry, Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, Texas.

Hürthle cell tumors (HCT), including Hürthle cell adenomas (HCA) and Hürthle cell carcinomas (HCCs), arise in the thyroid gland and are defined in part by an accumulation of mitochondria. These neoplasms were long considered a subtype of follicular neoplasm, although HCT is now generally considered a distinct entity. HCTs exhibit overlapping but distinct clinical features compared to follicular tumors, and several studies have demonstrated that HCTs harbor distinct genomic alterations compared to other forms of thyroid cancer. Read More

View Article

Download full-text PDF

Source
https://www.liebertpub.com/doi/10.1089/thy.2019.0088
Publisher Site
http://dx.doi.org/10.1089/thy.2019.0088DOI Listing
April 2019
22 Reads

Outcome and molecular characteristics of non-invasive encapsulated follicular variant of papillary thyroid carcinoma with oncocytic features.

Endocrine 2019 04 28;64(1):97-108. Epub 2019 Jan 28.

Department of Surgery, Memorial Sloan Kettering Cancer center, New York, NY, USA.

Purpose: In 2016, non-invasive encapsulated follicular variant of papillary thyroid carcinoma (NI-EFVPTC) was renamed as noninvasive thyroid follicular neoplasm with papillary-like nuclear features (NIFTP). However, as the study cohort did not mention tumors with oncocytic features, such lesions are still labeled by some as FVPTC. It is therefore crucial to evaluate the outcome and molecular profile of oncocytic NI-EFVPTC. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s12020-019-01848-6DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6657696PMC
April 2019
5 Reads
3.527 Impact Factor

Targetable gene fusions identified in radioactive iodine refractory advanced thyroid carcinoma.

Eur J Endocrinol 2019 Apr;180(4):235-241

Department of Pathology, Division of Endocrinology, Leiden University Medical Centre, Leiden, the Netherlands.

Objective Gene alterations leading to activation of the MAPK pathway are of interest for targeted therapy in patients with advanced radioactive iodine refractory (RAI-R) thyroid carcinoma. Due to technical reasons gene fusion analysis in RNA isolated from formalin-fixed tumor tissues has till now been limited. The objective of the present study was to identify targetable gene rearrangements in RNA isolated from formalin-fixed RAI-R thyroid carcinomas. Read More

View Article

Download full-text PDF

Source
https://eje.bioscientifica.com/view/journals/eje/aop/eje-18-
Publisher Site
http://dx.doi.org/10.1530/EJE-18-0653DOI Listing
April 2019
48 Reads

Radiation-associated epithelial-myoepithelial carcinoma among five secondary malignancies: A case report and review of literature.

World J Clin Oncol 2018 Dec;9(8):200-207

Department of Radiation Oncology, Vanderbilt University Medical Center, Nashville, TN 37232, United States.

Background: Epithelial-myoepithelial carcinoma (EMC) is a rare, low-grade, malignant tumor that constitutes less than one percent of all salivary gland tumors. To date, only one other case report has described radiation-associated EMC in the English language medical literature.

Case Summary: In this report, we describe the case of a 56-year-old male patient who presented with a neck mass diagnosed as EMC of the left submandibular gland approximately 30 years after mantle field radiation and chemotherapy for Hodgkin lymphoma. Read More

View Article

Download full-text PDF

Source
https://www.wjgnet.com/2218-4333/full/v9/i8/200.htm
Publisher Site
http://dx.doi.org/10.5306/wjco.v9.i8.200DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6314863PMC
December 2018
13 Reads

Metastatic Hurthle cell cancer.

QJM 2019 Jun;112(6):453-454

Department of Radiology, Universidade Federal do Rio de Janeiro, Rua Thomaz Cameron, 438, Valparaiso, CEP, Petrópolis, Rio de Janeiro, Brazil.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/qjmed/hcy297DOI Listing
June 2019
1 Read